Combination of modified albumin-bilirubin grade and platelet count to predict high-risk varices in patients with hepatocellular carcinoma

Prooksa Ananchuensook, Kingkomon Piyawannasuth, Sirinporn Suksawatamnuay, Panarat Thaimai, Nipaporn Siripon, Supachaya Sriphoosanaphan, Kessarin Thanapirom and Piyawat Komolmit

PLOS ONE, 2025, vol. 20, issue 7, 1-13

Abstract: Background: Variceal bleeding is associated with poor prognosis in patients with hepatocellular carcinoma. Therefore, it is essential to identify indicators of high-risk varices (HRV) and provide prompt intervention. Aim: To validate and modify albumin-bilirubin and platelet scores to predict high-risk varices in patients with hepatocellular carcinoma. Methods: We enrolled patients with hepatocellular carcinoma and esophagogastroduodenoscopy reports at King Chulalongkorn Memorial Hospital, Bangkok, Thailand, between 2015 and 2022. The nearest demographic and clinical characteristics and laboratory values were reviewed retrospectively within 6 months before the esophagogastroduodenoscopy. Albumin-bilirubin and platelet counts were calculated from the albumin-bilirubin grade plus score from platelet count. We evaluated the new modified albumin-bilirubin and platelet (mALBI-PLT)‘s in predicting HRV by dividing participants into a training cohort (first half) and a validation cohort (second half). Results: Of 564 patients with hepatocellular carcinoma, 277 were included. Most patients (232 [83.8%]) had Child-Turcotte-Pugh A cirrhosis, whereas 131 (47.3%), 85 (30.7%), and 60 (22.0%) had Barcelona Clinic Liver Cancer stages A, B, and C, respectively. Thirty-eight (15.6%) participants had HRV on esophagogastroduodenoscopy. On multivariate analysis, modified albumin-bilirubin grades 2b and 3 and platelet count ≤150,000/µL were significantly associated with HRV. Conclusion: Modified albumin-bilirubin grade and platelet at cut-off 150,000/µL exhibited significant association with high-risk varices in patients with hepatocellular carcinoma. Moreover, hepatocellular carcinoma patients with modified albumin-bilirubin grade 1 or 2a, together with platelets > 150,000/µL, may be able to avoid oesophagogastroduodenoscopy.

Date: 2025
References: Add references at CitEc
Citations:

Downloads: (external link)
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0327967 (text/html)
https://journals.plos.org/plosone/article/file?id= ... 27967&type=printable (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:plo:pone00:0327967

DOI: 10.1371/journal.pone.0327967

Access Statistics for this article

More articles in PLOS ONE from Public Library of Science
Bibliographic data for series maintained by plosone ().